drugset / Trial / NCT00677001
A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.
Phase 1
Completed
15 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen-Cilag Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety of R306465 (a drug in development for cancer) in patients with advanced cancer on the maximum dose that can be tolerated. Also, the absorption, breakdown and elimination of the drug will be studied.
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | R306465 | Small molecule | 100 mg | Oral |